Zeit | Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
---|---|---|---|---|---|
20.02. | IRLAB Therapeutics - EMA alignment on mesdopetam Phase III plans | 350 | Edison Investment Research | IRLAB has bolstered the value of its lead programme, mesdopetam in levodopa-induced dyskinesias (PD-LIDs), following confirmation that the European Medicines Agency (EMA) is aligned with the company... ► Artikel lesen | |
20.02. | Metlen (ASE: MYTIL) FY24 Results | 263 | Edison Investment Research | Metlen's FY24 results released on 20 February were broadly in line with consensus (EBITDA €1,080bn, 0.9% above consensus of €1,070bn and 2.4% above Edison of €1055bn, EPS €4.46, 2.2% below consensus... ► Artikel lesen | |
20.02. | Mendus - Vididencel on track in AML going into 2025 | 274 | Edison Investment Research | Mendus has reported its FY24 results, reflecting an active period. Lead programme, vididencel in acute myeloid leukaemia (AML), had encouraging data from the ADVANCE II trial in December, laying the... ► Artikel lesen | |
20.02. | Recce Pharmaceuticals - Positive R327G Phase II ABSSSI study results | 357 | Edison Investment Research | Recce has reported positive results from its open-label Phase II study assessing RECCE® 327 topical gel (R327G) in patients with acute bacterial skin and skin structure infections (ABSSSI), including... ► Artikel lesen |
Suchbegriffe der letzen 24 h | Anzahl |
---|---|
NVIDIA | 2.593 |
EVOTEC | 2.177 |
NOVO NORDISK | 1.656 |
RHEINMETALL | 1.087 |
TESLA | 1.031 |
RENK GROUP | 1.028 |
BYD | 828 |
TUI | 810 |
DEUTZ | 794 |
STEYR MOTORS | 785 |
SIEMENS ENERGY | 692 |
UNITEDHEALTH | 620 |
PLUG POWER | 583 |
NEL | 566 |
APPLE | 505 |
VOLKSWAGEN | 483 |
PUMA | 482 |
BASF | 447 |
ALMONTY | 439 |
ELI LILLY | 424 |
DEUTSCHE BANK | 422 |
BAYER | 420 |
MERCEDES-BENZ | 401 |
TSMC | 396 |
XIAOMI | 384 |